Patents by Inventor Muneeswara Babu Medi

Muneeswara Babu Medi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABLE FORMULATIONS OF CYTOMEGALOVIRUS
    Publication number: 20230277654
    Abstract: The present invention relates to stable formulations of a cytomegalovirus (CMV) comprising for example, a genetically modified CMV that is conditionally replication defective, a buffer, alkali or alkaline salt, a sugar, a cellulose derivative and optionally a polyol.
    Type: Application
    Filed: November 30, 2022
    Publication date: September 7, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Muneeswara Babu Medi, Harrison Bradford Davis, Lorenzo H. Chen, Lynne Ann Isopi, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler
  • ADJUVANTED VACCINES
    Publication number: 20230234850
    Abstract: Vaccine formulations are described comprising physically separated, lyophilized antigens and adjuvant components, which may be in lyoparticle form, as well as methods of using and making such formulations. Reconstituted formulations are also described.
    Type: Application
    Filed: February 22, 2023
    Publication date: July 27, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Akhilesh Bhambhani, Muneeswara Babu Medi, Maya Salnikova, William James Smith, David S. Thiriot
  • ADJUVANTED VACCINES
    Publication number: 20230192489
    Abstract: Vaccine formulations are described comprising physically separated, lyophilized antigens and adjuvant components, which may be in lyoparticle form, as well as methods of using and making such formulations. Reconstituted formulations are also described.
    Type: Application
    Filed: February 22, 2023
    Publication date: June 22, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Akhilesh Bhambhani, Muneeswara Babu Medi, Maya Salnikova, William James Smith, David S. Thiriot
  • FORMULATIONS AND PROCESSES FOR CAR T CELL DRUG PRODUCTS
    Publication number: 20220241329
    Abstract: Provided herein are formulations and drug product processes that can improve cell viability and minimize waste of the manufactured formulated cells for a drug product.
    Type: Application
    Filed: February 3, 2022
    Publication date: August 4, 2022
    Inventors: Muneeswara Babu MEDI, Zhuojin XU, Jung S. LEE, Yajin NI, Mark W. LEONARD
  • STABLE FORMULATIONS OF CYTOMEGALOVIRUS
    Publication number: 20210299247
    Abstract: The present invention relates to stable formulations of a cytomegalovirus (CMV) comprising for example, a genetically modified CMV that is conditionally replication defective, a buffer, alkali or alkaline salt, a sugar, a cellulose derivative and optionally a polyol.
    Type: Application
    Filed: October 29, 2018
    Publication date: September 30, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Muneeswara Babu Medi, Harrison Bradford Davis, Lorenzo H. Chen, Lynne Ann Isopi, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler
  • ADJUVANTED VACCINES
    Publication number: 20200325020
    Abstract: Vaccine formulations are described comprising physically separated, lyophilized antigens and adjuvant components, which may be in lyoparticle form, as well as methods of using and making such formulations. Reconstituted formulations are also described.
    Type: Application
    Filed: October 22, 2018
    Publication date: October 15, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Akhilesh Bhambhani, Muneeswara Babu Medi, Maya Salnikova, William James Smith, David S. Thiriot
  • Conditional replicating cytomegalovirus as a vaccine for CMV
    Patent number: 9546355
    Abstract: The present invention relates to methods of inducing an immune response to cytomegalovirus (CMV) using a genetically modified CMV that is conditionally replication defective. The methods of the invention can be used to treat and/or prevent primary CMV infection, infection due to reactivation of a latent CMV and a super-infection of a different strain of CMV that had been previously encountered. The present invention also relates to a replication defective CMV which has been recombinantly altered to allow for external control of viral replication. Compositions comprising the replication defective CMV are also encompassed by the present invention.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: January 17, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tong-Ming Fu, Dai Wang, Muneeswara Babu Medi
  • CONDITIONAL REPLICATING CYTOMEGALOVIRUS AS A VACCINE FOR CMV
    Publication number: 20140220062
    Abstract: The present invention relates to methods of inducing an immune response to cytomegalovirus (CMV) using a genetically modified CMV that is conditionally replication defective. The methods of the invention can be used to treat and/or prevent primary CMV infection, infection due to reactivation of a latent CMV and a super-infection of a different strain of CMV that had been previously encountered. The present invention also relates to a replication defective CMV which has been recombinantly altered to allow for external control of viral replication. Compositions comprising the replication defective CMV are also encompassed by the present invention.
    Type: Application
    Filed: September 4, 2012
    Publication date: August 7, 2014
    Inventors: Tong-Ming Fu, Dai Wang, Muneeswara Babu Medi